Seeking Alpha

Micromet (MITI +11.5%) says 75% of patients in a small phase-2 trial of its leukemia treatment...

Micromet (MITI +11.5%) says 75% of patients in a small phase-2 trial of its leukemia treatment blinatumomab achieved a complete remission, with no remaining cells in blood or bone marrow. MITI says the results are particularly striking given that the majority of enrolled patients had characteristics typically associated with a dismal outlook. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector